Cell and Gene Outsourcing

  1. Exploring The Spatial Distribution Of mRNA-Lipid Nanoparticles Using MALDI MSI 4/23/2025

    Learn how leveraging high-resolution MALDI-MSI can advance the development of lipid nanoparticle-based therapies, uncovering spatial biodistribution, pharmacokinetics, and organ-specific variability.

  2. Distribution Of Standard-Of-Care Antituberculosis Drugs In Cynomolgus Macaque Lungs 4/23/2025

    Incorporate individual variability into PBPK models and build on HRZE lung distribution data in NHPs to optimize anti-TB dosing strategies and advance PK/PD research in tuberculosis.

  3. Multimodal Stratification Of Predictive Biomarkers In Head And Neck Cancers 4/23/2025

    By identifying and utilizing predictive biomarkers, learn how researchers can enhance the effectiveness and safety of cytokine-based immunotherapy in head and neck cancers.

  4. Uncovering Novel Therapeutic Targets In Immune Checkpoint Inhibitor Resistance 4/23/2025

    Use spatial proteomics and AI-driven cell segmentation to reveal tumor-immune interactions and discover new targets to overcome resistance to immune checkpoint inhibitors in metastatic cancer.

  5. What CDMOs Wish Biotechs Knew Before Submitting An RFP 4/23/2025

    This author has worked with CDMOs across different programs and therapeutic modalities. Each experience reinforced the same lesson: a strong RFP can make or break a partnership.

  6. 8 Actions To Redefine Sponsor–CDMO Relationships 4/22/2025

    When viewing a CDMO as merely a service provider, interactions are often limited to completing tasks. This mindset can stifle innovation and problem-solving.

  7. Early-Phase Whole-Body PK 4/21/2025

    Accelerate your path to the clinic with Aliri’s cost-effective, label-free whole-body PK service — designed to deliver deeper insights, faster decisions, and better outcomes for your drug candidates.

  8. Label-Free Whole-Body Pharmacokinetics 4/21/2025

    This approach enables tissue-level analysis, delivering insights into efficacy at the site of action, uncovering potential safety concerns, and supporting smarter clinical candidate selection.

  9. What Is Causing Limited Bioavailability 4/21/2025

    Discover how this label-free whole-body QMSI combined with plasma LC-MS/MS can help identify the root causes of limited bioavailability and guide smarter optimization strategies early in development.

  10. Time: A Crucial Factor In Therapeutics Development 4/21/2025

    Accelerate your mRNA development and strengthen your response to emerging health threats with next-generation, cell-free DNA template solutions designed for speed, quality, and reliability.